NCT02820935View on ClinicalTrials.gov

Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Pharmacokinetics
Interventions
DRUG

CC-220

DRUG

Rifampin

DRUG

Itraconazole

Trial Locations (1)

78744

PPD Development, LP, Austin

Sponsors
All Listed Sponsors
lead

Celgene Corporation

INDUSTRY

NCT02820935 - Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects | Biotech Hunter | Biotech Hunter